Diabetic stress: new triumphs and challenges to maintain vascular longevity

References

• Maiese K, Chong ZZ, Shang YC. Mechanisitic insights into diabetes mellitus and oxidative stress. Curr. Med. Chem.14, 1689–1699 (2007).
   PubMed Web of Science ®Google Scholar
• Donahoe SM, Stewart GC, McCabe CH et al. Diabetes and mortality following acute coronary syndromes. JAMA298(7), 765–775 (2007).
   PubMed Web of Science ®Google Scholar
• Maiese K, Morhan SD, Chong ZZ. Oxidative stress biology and cell injury during type 1 and type 2 diabetes mellitus. Curr. Neurovasc. Res.4(1), 63–71 (2007).
   PubMed Web of Science ®Google Scholar
• Li F, Chong ZZ, Maiese K. Cell life versus cell longevity: the mysteries surrounding the NAD(+) precursor nicotinamide. Curr. Med. Chem.13(8), 883–895 (2006).
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Li F, Maiese K. Oxidative stress in the brain: novel cellular targets that govern survival during neurodegenerative disease. Prog. Neurobiol.75(3), 207–246 (2005).
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Kang JQ, Maiese K. Apaf-1, Bcl-xL, cytochrome c, and caspase-9 form the critical elements for cerebral vascular protection by erythropoietin. J. Cereb. Blood Flow Metab.23(3), 320–330 (2003).
   PubMed Web of Science ®Google Scholar
• Newsholme P, Haber EP, Hirabara SM et al. Diabetes associated cell stress and dysfunction: role of mitochondrial and non-mitochondrial ROS production and activity. J. Physiol.583(Pt 1), 9–24 (2007).
   PubMed Web of Science ®Google Scholar
• Monnier L, Mas E, Ginet C et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA295(14), 1681–1687 (2006).
   PubMed Web of Science ®Google Scholar
• Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA293(1), 90–95 (2005).
   PubMed Web of Science ®Google Scholar
• Symeonidis A, Kouraklis-Symeonidis A, Psiroyiannis A et al. Inappropriately low erythropoietin response for the degree of anemia in patients with noninsulin-dependent diabetes mellitus. Ann. Hematol.85(2), 79–85 (2006).
   PubMedGoogle Scholar
• Silverberg DS, Wexler D, Iaina A, Schwartz D. The interaction between heart failure and other heart diseases, renal failure, and anemia. Semin. Nephrol.26(4), 296–306 (2006).
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Kang JQ, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation106(23), 2973–2979 (2002).
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Maiese K. Erythropoietin involves the phosphatidylinositol 3-kinase pathway, 14–3-3 protein and FOXO3a nuclear trafficking to preserve endothelial cell integrity. Br. J. Pharmacol.150(7), 839–850 (2007).
   PubMed Web of Science ®Google Scholar
• Mikati MA, Hokayem JA, Sabban ME. Effects of a single dose of erythropoietin on subsequent seizure susceptibility in rats exposed to acute hypoxia at p10. Epilepsia48(1), 175–181 (2007).
   PubMed Web of Science ®Google Scholar
• Maiese K, Chong ZZ, Shang Y. “Sly as a FOXO”: new paths with forkhead signaling in the brain. Curr. Neurovasc. Res.4, 295–302 (2007).
   PubMed Web of Science ®Google Scholar
• Kuningas M, Magi R, Westendorp RG, Slagboom PE, Remm M, van Heemst D. Haplotypes in the human Foxo1a and Foxo3a genes; impact on disease and mortality at old age. Eur. J. Hum. Genet.15(3), 294–301 (2007).
   PubMed Web of Science ®Google Scholar
• Kamei Y, Miura S, Suzuki M et al. Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated Type I (slow twitch/red muscle) fiber genes, and impaired glycemic control. J. Biol. Chem.279(39), 41114–41123 (2004).
   PubMed Web of Science ®Google Scholar
• Olmos PR, Hodgson MI, Maiz A et al. Nicotinamide protected first-phase insulin response (FPIR) and prevented clinical disease in first-degree relatives of Type-1 diabetics. Diabetes Res. Clin. Pract.71(3), 320–333 (2005).
   PubMed Web of Science ®Google Scholar
• Crino A, Schiaffini R, Ciampalini P et al. A two year observational study of nicotinamide and intensive insulin therapy in patients with recent onset Type 1 diabetes mellitus. J. Pediatr. Endocrinol. Metab.18(8), 749–754 (2005).
   PubMed Web of Science ®Google Scholar
• Li F, Chong ZZ, Maiese K. Winding through the WNT pathway during cellular development and demise. Histol. Histopathol.21(1), 103–124 (2006).
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Li F, Maiese K. Cellular demise and inflammatory microglial activation during β-amyloid toxicity are governed by Wnt1 and canonical signaling pathways. Cell Signal.19(6), 1150–1162 (2007).
   PubMed Web of Science ®Google Scholar
• Lin CL, Wang JY, Huang YT, Kuo YH, Surendran K, Wang FS. Wnt/β-catenin signaling modulates survival of high glucose-stressed mesangial cells. J. Am. Soc. Nephrol.17(10), 2812–2120 (2006).
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Shang YC, Maiese K. Vascular injury during elevated glucose can be mitigated by erythropoietin and Wnt signaling. Curr. Neurovasc. Res.4(3), 194–204 (2007).
   PubMed Web of Science ®Google Scholar
• Mussmann R, Geese M, Harder F et al. Inhibition of glycogen synthase kinase (GSK) 3 promotes replication and survival of pancreatic β cells. J. Biol. Chem.282(16), 12030–12037 (2007).
   PubMed Web of Science ®Google Scholar
• Li F, Chong ZZ, Maiese K. Microglial integrity is maintained by erythropoietin through integration of Akt and its substrates of glycogen synthase kinase-3β, β-catenin, and nuclear factor-kB. Curr. Neurovasc. Res.3(3), 187–201 (2006).
   PubMed Web of Science ®Google Scholar
• Wu Y, Shang Y, Sun S, Liang H, Liu R. Erythropoietin prevents PC12 cells from 1-methyl-4-phenylpyridinium ion-induced apoptosis via the Akt/GSK-3β/caspase-3 mediated signaling pathway. Apoptosis12(8), 1365–1375 (2007).
   PubMed Web of Science ®Google Scholar
• Corwin HL, Gettinger A, Fabian TC et al. Efficacy and safety of epoetin α in critically ill patients. N. Engl. J. Med.357(10), 965–976 (2007).
   PubMed Web of Science ®Google Scholar
• Kokhaei P, Abdalla AO, Hansson L et al. Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies. Clin. Cancer Res.13(12), 3536–3544 (2007).
   PubMed Web of Science ®Google Scholar
• Maiese K, Li F, Chong ZZ. Erythropoietin and cancer. JAMA293(15), 1858–1859 (2005).
   PubMedGoogle Scholar
• Emami KH, Corey E. When prostate cancer meets bone: control by wnts. Cancer Lett.253(2), 170–179 (2007).
   PubMed Web of Science ®Google Scholar
• Saunders LR, Verdin E. Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene26(37), 5489–5504 (2007).
   PubMed Web of Science ®Google Scholar